One of the most common birth defects worldwide is hearing loss. Every 1,000 babies born worldwide are affected by permanent hearing loss in one or both ears. Hearing loss can significantly affect a baby's development.
CapitalBiotech has developed the Hereditary Deafness Gene Detection Assay using semiconductor sequencing technology. It can identify 100 mutant sites on 18 deafness-related genes such as GJB2, SLA26A4, GJB3, MT-RNR1, and others. This detection assay boasts an accuracy of over 99.9%.
The BioElectron Gene Squencer 4000 platform was developed in collaboration with Thermo Fisher. It can detect 384 samples simultaneously.
What is In Vitro Diagnostic Reagents?April 4, 2023In vitro diagnostic reagents refer to in vitro diagnostic reagents managed by medical device management, including reagents, reagent kits, calibration products, quality control products, etc. used for...view
The Role of Microfluidic Platforms in Drug Development and TestingJuly 18, 2024In the dynamic landscape of drug development and testing, the advent of microfluidic technology stands as a revolutionary advancement. Among the frontrunners in this innovation is CapitalBio, a brand ...view
Next Generation Sequencing (NGS) TechnologyApril 8, 2024Next Generation Sequencing (NGS), also known as high-throughput sequencing, revolutionized the field of genomics. Unlike traditional Sanger sequencing methods, NGS allows researchers to analyze vast a...view